The Laboratory Report Winter 2011

The

Winter 2011

Laboratory Report A Publication of the Department of Pathology and Genomic Medicine

Department and Houston Society of Clinical Pathologists to Host Major Symposium

T

he Department of Pathology and Genomic Medicine is collaborating with the Houston Society of Clinical Pathologists (HSCP) to host a major symposium at Methodist in 2012. The Spring Symposium of the HSCP and the Department’s Seminar on Advances in Lung Cancer will combine for a two-day event on April 28th and 29th in The Methodist Hospital Research Institute auditorium.

The event, the Houston Lung Symposium, is the brainchild of Dr. Philip Cagle, medical director of pulmonary pathology for the Department and editor-in-chief of Archives of Pathology and Laboratory Medicine.

“This symposium will convene some of the most accomplished pathologists,

Dr. Cagle in the Research Institute auditorium.

oncologists, and bioinformatics experts from Houston and around the world,” said Dr. Cagle. “This is an excellent opportunity for physicians, scientists, and trainees at all levels.”

The symposium will feature 20 speakers from institutions including

Methodist, The University of Texas M.D. Anderson Cancer Center, the Mayo Clinic, Harvard Medical School, and the Memorial Sloan-Kettering Cancer Center.

Lectures on April 28th will involve various topics in diagnostic pulmonary pathology, while those on April 29th will cover the current status and future directions of lung cancer diagnosis and treatment. Seating for the Houston Lung Symposium will be limited, registration is required, and advance registration is highly recommended.

To register for the symposium or obtain the speaker agenda, visit houstonpathologists.org/upcomingevents. 

Table of Contents

In Our Next Issue...

Dr. Michael Thrall is leading the Department’s efforts to implement digital pathology technology into specific clinical services in 2012. This cutting-edge technology will allow for more rapid diagnoses for our patients and will enhance education programs.

Look for a complete article on digital pathology at Methodist in the spring 2012 issue of The Laboratory Report!

2

Laboratory Outreach Grows with The Methodist Hospital Reference Laboratories New Faculty Join Department

3 4

New Diagnostic Test Offerings Sugar Land Laboratory Supports Breast Center Expansion Trainee Spotlight Dr. Adriana Rosato Leads Methicillin-Resistant Staphylococcus Aureus Research Effort

5 The Laboratory Report—Issue Archives Would you like to view past issues of The Laboratory Report? All 2011 issues can be viewed by visiting our Department website at methodisthealth.com/TheLaboratoryReport.

Dr. Bogdan Czerniak to Present Chair’s Lectureship Dr. Wayne Chandler Leads Test Utilization Improvement Effort

The

LABORATORY REPORT

2

Laboratory Outreach Grows with The Methodist Hospital Reference Laboratories

T

he Department of Pathology and Genomic Medicine and The Methodist Hospital are further developing and expanding their laboratory outreach program with the formation of The Methodist Hospital Reference Laboratories (TMHRL). TMHRL will provide expanded clinical testing for The Methodist Hospital patients, additional testing volume for esoteric tests, and method development and teaching opportunities for residents and fellows.

“This is a tremendous opportunity for the Department and the hospital,” said Dr. Wayne Chandler, vice-chair of clinical innovation for the Department. “In addition to helping our institution, our program can provide a service that helps other institutions and providers improve their standard of care. It’s a win-win situation.” TMHRL extends the Department’s clinical services and expertise to

subscribing non-Methodist hospitals, multi-specialty provider groups, and academic and commercial research groups.

“The Methodist reputation for excellence in patient care is strong, our department faculty members are renowned in their specialty and subspecialty fields, and we have great facilities,” said Phuong Nguyen, outreach specialist for TMHRL. “While the program has done well, it has the potential to be much bigger and better.” New infrastructure for the program is in the final stages of development, and a stateof-the-art test ordering and results delivery system is being implemented with the latest generation of operating system

Dr. Chandler and Phuong Nguyen.

interface software. A website will be launched in early 2012.

For more information on TMHRL, please contact Phuong Nguyen at 713-441-3484 or ptnguyen@tmhs.org. 

New Faculty Join Department

T

he Department of Pathology and Genomic Medicine continues to grow. Two new physicians have recently joined our faculty:

Lauri B. Campagna, M.D. Staff Pathologist, Methodist West Houston Hospital Dr. Campagna joins the Department from The University of Texas Southwestern Medical Center in Dallas, TX where she was an assistant professor of surgical pathology and cytopathology. She received her medical degree in 1991 from the University of Colorado School of Medicine in Denver, CO. She completed an anatomic and clinical pathology residency and a cytopathology fellowship at Methodist and the Baylor College of Medicine in Houston, TX. Dr. Campagna will primarily provide anatomic and clinical pathology services at Methodist West Houston Hospital.

For more information on Dr. Campagna, visit methodisthealth.com/Campagna. 

Bisong Haupt, M.D. Staff Pathologist, Methodist Sugar Land Hospital Dr. Haupt is an alumna of the pathology training programs here at Methodist where she completed both an anatomic and clinical pathology residency and a surgical pathology fellowship. She rejoins the Department from St. Louis University in St. Louis, MO where she was an assistant professor of pathology. Dr. Haupt received her medical degree in 1982 from the Southeast University School of Medicine in Nanjing, China. She will primarily provide anatomic and clinical pathology services at Methodist Sugar land Hospital.

For more information on Dr. Haupt, visit methodisthealth.com/Haupt. 

The

LABORATORY REPORT

3

New Diagnostic Test Offerings: Adenovirus Real-Time PCR Assay The Molecular Diagnostics Laboratory of The Methodist Hospital System has implemented a new real-time PCR assay to detect adenovirus. Adenoviruses are DNA viruses that cause several infectious manifestations, including gastroenteritis, pneumonia, conjunctivitis, and skin rashes. Importantly, adenovirus infection can lead to graft failure and life threatening disseminated disease in transplant patients.

Real-time PCR is a highly sensitive and specific method to detect the presence of DNA from pathogens in clinical specimens. The adenovirus real-time PCR assay is the latest in a series of new molecular tests instituted by the Molecular Diagnostics Laboratory. This test, which was previously performed at a reference laboratory, was introduced in-house on November 1. Performing the test at Methodist will improve patient care by increasing quality, decreasing costs, and minimizing turnaround times.

For more information on this assay or other tests offered by the TMHS Molecular Diagnostics Laboratory, please contact Dr. Randall Olsen at 713-441-6802 (rjolsen@tmhs.org) or Brant Hilson at 713441-5725 (bhilson@tmhs.org). 

BinaxNOW Malaria Test and Helicobacter pylori Stool Antigen Test The Clinical Microbiology Laboratory of The Methodist Hospital System will be offering two new antigen detection assays in December: the BinaxNOW malaria test by Inverness Medical and the Helicobacter pylori Stool Antigen (HpSA) test by Meridian Biosciences, Inc. The BinaxNOW malaria test is an immunochromatographic assay for the qualitative detection of Plasmodium antigens. It targets the histidine-rich protein II (HRPII), which is a specific antigen common to all four malaria species capable of causing human infection - P. falciparum, P. vivax, P. ovale, and P. malariae.

The BinaxNOW assay is to be used in conjunction with a malaria peripheral blood smear. Although the BinaxNOW assay is less sensitive than the malaria 

BinaxNOW cont. smear, it can provide results in 15 minutes. The advantage of this assay is that it allows for rapid identification and quicker implementation of therapy.

The HpSA test is an enzyme immunoassay that detects Helicobacter pylori proteins in human stool. This assay has demonstrated higher sensitivity and specificity than serology or the urea breath test, and thus is an important option in the non-invasive diagnosis of H. pylori.

For more information on the BinaxNOW malaria test or the HpSA test, please contact Dr. James Davis at 713-441 -2437 or Pat Cernoch at 713-441-0333. 

BreathTek C-13 Urea Breath Test The Outpatient Laboratory in Smith Tower (Room 523) now offers the BreathTek C-13 urea breath test to aid in the initial diagnosis and post-treatment monitoring of active Helicobacter pylori infection. H. pylori is a Gram-negative, microaerophilic bacterium found in the stomach which causes duodenal and gastric ulcers, and has been linked to the development of stomach cancer. Several studies have reported that initial antimicrobial therapies can fail in as many as 1 in 4 patients, so post-treatment monitoring is important.

The BreathTek test from Otsuka America Pharmaceuticals is an easy, convenient non-invasive and non-radioactive test and can be administered in about 15 minutes. Patients should fast for at least one hour and refrain from using antimicrobials, proton pump inhibitors, or bismuth preparations for two weeks prior to testing.

For more information on the BreathTek C-13 urea breath test, please contact Dr. Ping Wang at pwang@tmhs.org or Tammy Lefevers at tlefevers@tmhs.org. 

MALDI-TOF Mass Spectrometry The Bruker BioTyper is now being used in the Microbiology Laboratory. This new MALDI-TOF mass spectrometer rapidly identifies bacteria based on their

MALDI-TOF cont. unique protein fingerprints. Validation studies for Gram-negative organisms were completed in December. Additional validations for identifying yeast and Gram-positive bacteria are ongoing. Implementation of this exciting new technology at The Methodist Hospital will significantly improve patient care by increasing sensitivity and reducing turnaround times.

For more information on the BioTyper MALDI-TOF mass spectrometer, please contact Dr. James Davis at 713-441-2437 or Pat Cernoch at 713-441-0333.  Triage TOX Drug Screen The Triage TOX Drug Screen (Triage Drugs of Abuse Panel) from Alere now also tests for the presence of methamphetamines and methadone. The assay has also changed from a visually interpreted chromogenic immunoassay to an automated fluorescence immunoassay.

The panel is highly accurate and screens for up to 10 distinct classes of abused drugs (illicit and prescription) with results obtained in approximately 15 minutes. The screen includes assays for the presence of amphetamines, methamphetamines, barbiturates, benzodiazepines, cocaine, methadone, opiates, phencyclidine, tetrahydrocannabinol, and tricyclic antidepressants.

This screen is especially useful in obtaining a differential diagnosis for emergency medicine cases that may or may not involve drug abuse as a primary cause or contributing factor. It is recommended that preliminary positive results from the screen be confirmed with gas chromatography-mass spectroscopy. At Methodist, acetaminophen/paracetamol is assessed using a quantitative serum measurement assay run on the Vitros Fusion platform.

For more information on the improved Triage TOX Drug Screen, contact Dr. Ping Wang at pwang@tmhs.org or Toni Emmott at temmott@tmhs.org. 

The

LABORATORY REPORT

4

Sugar Land Laboratory Supports Breast Center Expansion

T

he Breast Center at Methodist Sugar Land Hospital has undergone a significant expansion to meet the needs of the growing Fort Bend County community. The new facility is larger and provides the full continuum of care – from screening through treatment and survivorship – all in one integrated and multidisciplinary setting.

“Tissue diagnosis is a critical part of the multidisciplinary treatment plan of breast cancer,” said Dr. Seema Mullick, medical director of Laboratory Services at Methodist Sugar Land

Dr. Mullick in the Sugar Land laboratory.

Hospital. “Our goal is to provide an accurate and timely biopsy report to facilitate the personalized care that each of our patients receive here at Methodist Sugar Land Hospital.”

Breast biopsies and related anatomic pathology volumes have risen considerably since the Breast Center moved to its new location in February. The laboratory is expected to assess more than 800 breast biopsies in 2012.

For more information on Methodist Sugar Land Hospital, visit methodisthealth.com/sugarland. 

Trainee Spotlight: Elizabeth B. McQuitty, M.D. PGY4 Resident

D

r. Elizabeth McQuitty, a PGY4 resident, received a first place award for her oral abstract presentation, “CD8-positive CD30-positive lymphomatoid papulosis and its differential diagnosis: a review of 20 cases”, at the 48 th Annual Meeting of the American Society of Dermatopathology (ASDP) in Seattle, WA. She is also developing a text book with Dr. Jae Ro on evidenced-based approaches to cancer diagnosis.

Dr. McQuitty received her Master of Architecture degree from Rice University in 2002. She then pursued a medical degree from the Baylor College of Medicine where she was a member of the Alpha Omega Alpha Honor Medical Society. She graduated in 2008 and joined the pathology residency program at Methodist that same year. Dr. McQuitty will complete a fellowship in molecular genetic pathology at Methodist in 2012.

Elizabeth McQuitty, M.D.

Dr. Adriana Rosato Leads Methicillin-Resistant Staphylococcus Aureus Research Effort

D

r. Adriana Rosato, a research scientist in the Center for Molecular and Translational Human Infectious Diseases Research, is leading the Department’s efforts to investigate the pathogenesis of multidrugresistant bacteria. With a five-year R01 grant from the National Institute of Allergy and Infectious Diseases, her research aims to identify molecular genetic causes of drug resistance in methicillinresistant Staphylococcus aureus (MRSA).

“MRSA strains with low-level antibiotic resistance are a serious concern in hospital settings and, more recently, the community,” said Dr. Rosato. “Data from our studies could identify new drug targets for development of a novel class of antibiotics.”

Dr. Rosato is also investigating the mechanistic bases and molecular pathways involved in resistance to daptomycin, a new class of cyclic lipopeptide antibiotic that is effective against MRSA. Although daptomycin-resistant S. aureus infections are extremely rare, they pose a considerable treatment challenge when they occur as optimal therapy remains undefined and the infections commonly appear in patients with complicated preexisting, deepseated infections such as osteomyelitis, septic arthritis, or endocarditis.

For more information on Dr. Rosato,

Dr. Rosato in the laboratory.

visit methodisthealth.com/Rosato. 

The

LABORATORY REPORT

5

Dr. Bogdan Czerniak to Present Chair’s Lectureship

Bogdan Czerniak, M.D., Ph.D.

D

r. Bogdan Czerniak, chairman ad interim and deputy division head for research in the Department of Pathology at The University of Texas M.D. Anderson Cancer Center,

will present the Chair’s Lectureship at the Methodist Department of Pathology and Genomic Medicine Grand Rounds on Tuesday, February 7, 2012. Dr. Czerniak, a renowned genitourinary pathology expert, will speak on molecular pathology as it relates to bladder cancer development and detection.

“Understanding the molecular genetic basis of bladder cancers has allowed us to develop promising new non-invasive tests that detect the cancers in their earliest stages,” said Dr. Czerniak. “Genomic research will ultimately provide us with the information we need to improve the standard of care for this patient population – and many others.”

Dr. Czerniak’s research focuses on early events of carcinogenesis using human bladder cancer as a model disease.

His laboratory is credited with the development of a strategy that combines

whole-organ topographic histologic and molecular mapping. This approach has provided unique information on initiating cancer events and on the existence of a novel class of genes, termed forerunner genes, which contribute to early expansion of intraurothelial neoplasia by their loss of function.

The Department of Pathology and Genomic Medicine Grand Rounds program was established in 2010 and is directed

by Dr. Geoffrey Land, medical director of histocompatibility and transplant immunology for the Department.

For more information on the Department Grand Rounds or a list of speakers with dates and topics, visit methodisthealth.com/pathologygrandrounds or contact Victoria Watson at vlwatson@tmhs.org. 

Dr. Wayne Chandler Leads Test Utilization Improvement Effort

T

est utilization management programs aim to evaluate the clinical and fiscal effects of test ordering with the goal of improving patient care, increasing efficiency, and reducing costs. Dr. Wayne Chandler, vice-chair for clinical innovation in the Department, is directing such an effort at Methodist.

“Laboratory testing should provide the necessary clinical information to the physician and use laboratory services appropriately and effectively,” said Dr. Chandler. “Advances in medical research and testing technology are continuously affecting evidencebased guidelines for patient care. It is imperative that Methodist continually monitor these changes and manage test utilization accordingly.”

Dr. Chandler and colleagues at the University of Washington and Johns Hopkins Hospitals have conducted several

Dr. Chandler meets with Laboratory Technologists, Heather Hendrickson (left) and Pam McShane (right).

studies on test utilization. Their 2009 study focused on ionized calcium testing and their most recent study, published in Blood Coagulation and Fibrinolysis, investigated the overuse of coagulation test panels. Dr. Chandler and colleagues found that the common cycle of calcium screening and supplementation in unselected patients (patients without known

or suspected specific derangements in calcium metabolism) had no positive effect on outcomes. They also found that the automated total calcium test was a clinically suitable screening test to determine the need for an ionized calcium test in this patient population. Their most recent study found that coagulation test panels are significantly overused and often not clinically indicated, and that the prothrombin time test more often diagnosed vitamin K deficiency than bleeding risk. The latter study also evaluated the most effective methods of implementing change in clinical test utilization. Implementation of new test utilization practices at Methodist will begin in 2012.

For more information on test utilization management at Methodist, please contact Dr. Wayne Chandler at wlchandler@tmhs.org. 

The

LABORATORY REPORT

6

RECENT PUBLICATIONS Ahmed N, Salsman V, Kew Y, Shaffer D, Powell S, Zhang Y, Grossman R, Heslop H, Gottschalk S. Generation of polyclonal CMVspecific T cells for the adoptive immunotherapy of glioblastoma. Journal of Immunotherapy. 2011, In Press.

Amukele TK, Baird GS, Chandler WL. Reducing the use of coagulation test panels. Blood Coagul Fibrinolysis. 2011 Sep 19 [Epub ahead of print] Bond WS, Wadhwa L, Perlaky L, Penland RL, Hurwitz MY, Hurwitz RL, Chèvez-Barrios P. Establishment and propagation of human retinoblastoma tumors in immune deficient mice. J Vis Exp. 2011 Aug 4;(54).

Carroll RK, Beres SB, Sitkiewicz I, Peterson L, Matsunami RK, Engler DA, Flores AR, Sumby P, Musser JM. Evolution of diversity in epidemics revealed by analysis of the human bacterial pathogen group A Streptococcus. Epidemics. 2011 Sep;3(3-4):159-70.

Deleo FR, Kennedy AD, Chen L, Bubeck Wardenburg J, Kobayashi SD, Mathema B, Braughton KR, Whitney AR, Villaruz AE, Martens CA, Porcella SF, McGavin MJ, Otto M, Musser JM, Kreiswirth BN. Molecular differentiation of historic phage-type 80/81 and contemporary epidemic Staphylococcus aureus. Proc Natl Acad Sci U S A. 2011 Nov 1;108(44):18091-6.

Dhar SU, Chintagumpala M, Noll C, Chévez-Barrios P, Paysse EA, Plon SE. Outcomes of integrating genetics in management of patients with retinoblastoma. Arch Ophthalmol. 2011 Nov;129(11):1428-34.

Feske ML, Medina M, Graviss EA, Lewis DE. IL-7 addition increases spot size and number as measured by T-SPOT.TB (®). Methods Mol Biol. 2012;792:229-41.

Feske ML, Teeter LD, Musser JM, Graviss EA. Giving TB wheels: Public transportation as a risk factor for tuberculosis transmission.

Tuberculosis (Edinb). 2011 Nov 14. [Epub ahead of print] Feske ML, Teeter LD, Musser JM, Graviss EA. Including the third dimension: A spatial analysis of TB cases in Houston Harris County.Tuberculosis (Edinb). 2011 Nov 15. [Epub ahead of print] Gao L, Li F, Thrall MJ, Yang Y, Xing J, Hammoudi AA, Zhao H, Massoud Y, Cagle PT, Fan Y, Wong KK, Wang Z, Wong ST. On-thespot lung cancer differential diagnosis by label-free, molecular vibrational imaging and knowledge-based classification. J Biomed Opt. 2011 Sep;16(9):096004.

Hawiger J, Musser JM. How to approach genome wars in sepsis? Crit Care. 2011 Dec 2;15(6):1007. [Epub ahead of print] Horstmann N, Sahasrabhojane P, Suber B, Kumaraswami M, Olsen RJ, Flores A, Musser JM, Brennan RG, Shelburne SA 3rd. Distinct single amino Acid replacements in the control of virulence regulator protein differentially impact streptococcal pathogenesis. PLoS Pathog. 2011 Oct;7(10):e1002311.

Kosarac O, Zhai QJ, Shen S, Takei H, Ro JY, Ayala AG. Minimal or no residual prostatic adenocarcinoma on radical prostatectomy: a 5-year experience with "vanishing carcinoma phenomenon". Arch Pathol Lab Med. 2011 Nov;135(11):1466-70.

Koshy JC, Goldberg JS, Wolfswinkel EM, Ge Y, Heller L. Breast cancer incidence in adolescent males undergoing subcutaneous mastectomy for gynecomastia: is pathologic examination justified? A retrospective and literature review. Plast Reconstr Surg. 2011 Jan;127 (1):1-7.

Kum JB, Grignon DJ, Wang M, Zhou M, Montironi R, Shen SS, Zhang S, Lopez-Beltran A, Eble JN, Cheng L. Mixed epithelial and stromal tumors of the kidney: evidence for a single cell of origin with capacity for epithelial and stromal differentiation. Am J Surg Pathol. 2011 Aug;35(8):1114-22.

Kwon GY, Ro JY. Micropapillary variant of urothelial carcinoma. Adv Urol. 2011;2011:217153.

Lee H, Choi SK, Ro JY. Overexpression of DJ-1 and HSP90α and loss of PTEN associated with invasive urothelial carcinoma of urinary bladder: possible prognostic markers. Oncology Letters. 2011, In Press.

McCall B, Pierce M, Graviss EA, Richards-Kortum R, Tkaczyk T. Toward a low-cost compact array microscopy platform for detection of tuberculosis. Tuberculosis (Edinb). 2011 Nov 10. [Epub ahead of print] Mehta S, Cuirolo AX, Plata KB, Riosa S, Silverman JA, Rubio A, Rosato RR, Rosato AE. VraSR two-component regulatory system contributes to mprF-mediated decreased susceptibility to daptomycin in-vivo-selected MRSA clinical strains. Antimicrob Agents Chemother. 2011 Oct 10. [Epub ahead of print] Merritt WM, Kamat AA, Hwang JY, Bottsford-Miller J, Lu C, Lin YG, Coffey D, Spannuth W, Nugent E, Han LY, Landen CN, Nick AM, Stone RL, Coffman KT, Bruckheimer E, Broaddus R, Gershenson DM, Coleman RL, Sood AK. Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer. Cancer Biol Ther. 2011 Jan 12;10(12):1306-14.

Continued page 7

The

LABORATORY REPORT

7

RECENT PUBLICATIONS continued Nakhleh RE, Myer JL, Allen TC, Deyoung BR, Fitzgibbons PL, Funkhouser WK, Mody DR, Lynn A, Fatheree LA, Smith AT, Lal A, Silverman JF. Consensus Statement on Effective Communication of Urgent Diagnoses and Significant, Unexpected Diagnoses in Surgical Pathology and Cytopathology From the College of American Pathologists and Association of Directors of Anatomic and Surgical Pathology. Arch Pathol Lab Med. 2011 Oct 13. [Epub ahead of print] Nguyen DTM, NQ Hung, LT Giang, NH Dung, NTN Lan, NN Lan, NTB Yen, ND Bang, DV Ngoc, LTT Trinh, RP Beasley, L-Y Hwang, EA Graviss. 2011. Improving the Diagnosis of Pulmonary Tuberculosis in HIV-Infected Individuals in Ho Chi Minh City, Vietnam. Int J Tuberc Lung Dis. 2011 Nov;15(11):1528-35.

Ozcan A, Liles N, Coffey D, Shen SS, Truong LD. PAX2 and PAX8 Expression in Primary and Metastatic MĂźllerian Epithelial Tumors: A Comprehensive Comparison. Am J Surg Pathol. 2011 Dec;35(12):1837-47.

Powell SZ. Changes in residency training: shaping the future pathology workforce. Critical Values. 2011, In Press.

Ragunathan A, Olar A, Vogel H, Powell S, Fuller GN, Cahill D, Parker J, Aldape K. Isocitrate dehydrogenase 1 (IDH1) R132H mutation is not detected in angiocentric glioma. Annals of Diagnostic Pathology. 2011, In Press.

Ro JY. Are elastic stain and specialty sign out necessary to evaluate pleural invasion in lung cancers? Annals of Diagnostic Pathology.

2011, In Press.

Shea PR, Ewbank AL, Gonzalez-Lugo JH, Martagon-Rosado AJ, Martinez-Gutierrez JC, Rehman HA, Serrano-Gonzalez M, Fittipaldi N, Beres SB, Flores AR, Low DE, Willey BM, Musser JM. Group A Streptococcus emm Gene Types in Pharyngeal Isolates, Ontario, Canada, 2002-2010. Emerg Infect Dis. 2011 Nov;17(11):2010-7.

Shelburne Iii SA, Olsen RJ, Makthal N, Brown NG, Sahasrabhojane P, Watkins EM, Palzkill T, Musser JM, Kumaraswami M. An amino-terminal signal peptide of Vfr protein negatively influences RopB-dependent SpeB expression and attenuates virulence in Streptococcus pyogenes. Mol Microbiol. 2011 Oct 31. [Epub ahead of print] Shin SJ, Kim KR, Song DE, Ro JY, Kong KY, Lee SW, Nam JH. Recognition of parametrial invasion, an important landmark when treating cervical cancer. Gynecol Oncol. 2011 Nov 18. [Epub ahead of print] Sniecinski RM, Chandler WL. Review articles: activation of the hemostatic system during cardiopulmonary bypass. Anesth Analg.

2011 Dec;113(6):1319-33.

Son DH, Ro JY, Kang MJ, Jang WY, Cho YM. Histology and distribution of prostatic tissue on prostatic urethral margins: evaluation of radical prostatectomy specimens and implications on frozen section analysis. Ann Diagn Pathol. 2011 Nov 1. [Epub ahead of print] Stancel GA, Coffey D, Alvarez K, Halks-Miller M, Lal A, Mody D, Koen T, Fairley T, Monzon FA. Identification of tissue of origin in body fluid specimens using a gene expression microarray assay. Cancer Cytopathol. 2011 Jun 29. [Epub ahead of print] Wang P. Statin dose in Asians: is pharmacogenetics relevant? Pharmacogenomics. 2011 Nov;12(11):1605-15.

Yang Y, Li F, Gao L, Wang Z, Thrall MJ, Shen SS, Wong KK, Wong ST. Differential diagnosis of breast cancer using quantitative, label-free and molecular vibrational imaging. Biomed Opt Express. 2011 Aug 1;2(8):2160-74.

Zarrin-Khameh N, Haas EM, Ro J, Thrall MJ. Lipomatosis coli, a mimicker of familial polyposis. Ann Diagn Pathol. 2011 Nov 4. [Epub ahead of print] Zhang S, Zheng M, Kibe R, Huang Y, Marrero L, Warren S, Zieske AW, Iwakuma T, Kolls JK, Cui Y. Trp53 negatively regulates autoimmunity via the STAT3-Th17 axis. FASEB J. 2011 Jul;25(7):2387-98.

Zhao N, Fogg JM, Zechiedrich L, Zu Y. Transfection of shRNA-encoding Minivector DNA of a few hundred base pairs to regulate gene expression in lymphoma cells. Gene Ther. 2011 Mar;18(3):220-4. ď Ž

The Laboratory Report The Laboratory Report is a publication of The Methodist Hospital System Department of Pathology and Genomic Medicine.

Editor-in-Chief April A. Ewton, M.D.

Claudia P. Molina, M.D. Seema Mullick, M.D. Editorial Committee Thu Ngo, M.D. Hazel L. Awalt, M.D. Steven Shen, M.D., Ph.D. Christopher Leveque, M.D. Paul Sumby, Ph.D.

Ping Wang, Ph.D. Editorial Coordinator Philip Randall

The Methodist Hospital Clare Rose, M.B.A. Manuel Hinojosa, M.H.A.

Department Chair James M. Musser, M.D., Ph.D.